alkotinib
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2018 (NCT03607188)
Timeline
Indications
Studied for
Mechanism of action
- ALK tyrosine kinase receptorINHIBITOR
ALK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04211922 | Phase 2 | Dec 27, 2019 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT04032821 | Phase 1 | Sep 10, 2019 | Jilin University, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT03607188 | Phase 1 | Aug 1, 2018 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | For profit | 3 | 3 | 2 | 2018 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1